bladder cancer

Trials explore immune checkpoint blockade in NMIBCPeter C. Black, MD, discusses the current state of immune checkpoint inhibition for bladder cancer in this article from Urology Times SUO internship program member William Parker, MD.
AstraZeneca drug a breakthrough therapy for bladder cancerFDA has granted breakthrough therapy designation for durvalumab (MEDI4736, AstraZeneca) for the treatment of urothelial bladder cancer.
Bladder cancer tests: What factors impact results?Urology Times SUO internship program member Katie Murray, DO, reports on a study evaluating the differences in urine cytology and UroVysion FISH testing results among clinically meaningful patient subgroups.
Study weighs impact of BCG shortage on outcomesUrology Times SUO internship program member William Parker, MD, discusses a retrospective review of more than 100 patients at Columbia University Medical Center in New York.
Uro Pipeline: 1st patients treated in phase III study of investigational BPH TxOther pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
Uro Pipeline: Phase III data show drug’s benefit in castrate-resistant PCaOther pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.
Uro Pipeline: IDE approval granted for implantable neurostimulatorA prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
Work-related bladder cancer risk on the riseWork-related risks for bladder cancer are on the rise, but the occupations putting workers at risk seem to be evolving, according to a meta-analysis published online in JAMA Oncology (Oct. 8, 2015).
The promise of PD-1 ligand pathway in treating bladder cancerResearchers have recently made progress in understanding a fundamental signaling cascade, the Programmed Death 1 (PD-1) receptor-ligand pathway,1 which holds long-awaited promise in bladder cancer intervention.
Reprogramming cancer with a codeResearchers at Mayo Clinic’s Jacksonville, Fla., campus reported a discovery that could be the code for reprogramming cancer cells back to normal.